Who is sponsoring NCT05206422?

NCT05206422 is sponsored by Revamp Medical Inc..

What drugs are being tested in NCT05206422?

Interventions in NCT05206422: Doraya Catheter.

What condition does NCT05206422 study?

NCT05206422 studies Acute Decompensated Heart Failure.

Is NCT05206422 still recruiting?

NCT05206422 is currently active, enrolled. Last updated 9 March 2026.

Last reviewed 2026-03-09 · How we verify

NCT05206422

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DORAYA-HF Early Feasibility Study

Active, enrolled NA Last updated 9 March 2026

What this trial tests

NA trial testing Doraya Catheter in Acute Decompensated Heart Failure in 30 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

5 October 2022

Primary endpoint
31 January 2026

31 March 2026

Quick facts

Lead sponsor	Revamp Medical Inc.
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	5 October 2022
Primary completion	31 January 2026
Estimated completion	31 March 2026
Sites	14 locations across United States

Drugs / interventions tested

Doraya Catheter

Conditions studied

Acute Decompensated Heart Failure — all drugs for Acute Decompensated Heart Failure →

Sponsor

Revamp Medical Inc. — full company profile →

Who can join

18 and older, any sex, with Acute Decompensated Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study objective is to evaluate the feasibility of the Doraya Catheter and measure clinical performance and safety endpoints, in ADHF patients deemed to have insufficient diuretic response.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Patient Selection and End Point Definitions for Decongestion Studies in Acute Decompensated Heart Failure: Part 1.
Georges G, Fudim M, Burkhoff D, Leon MB, et al · · 2023 · cited 3× · PMID 39131061 · DOI 10.1016/j.jscai.2023.101060

Verify or expand the search:

Other recruiting trials for Acute Decompensated Heart Failure

Currently open trials in the same condition.

NCT07372040 — Add-on Diuretics in Acute Decompensated Heart Failure · Phase 2 · recruiting
NCT07199088 — Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Ac · NA · recruiting
NCT03951467 — Using an Intervention Adapted to the Health Literacy Level to Improve Adherence to Medical Recommendations · NA · recruiting
NCT06556810 — IC14 for Treatment of Acute Decompensated Heart Failure · Phase 1, PHASE2 · active not recruiting
NCT06714409 — Venous Ultrasound Guided Organ Decongestion in Patients Hospitalized with Acute Decompensated Heart Failure · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05206422 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Revamp Medical Inc.
Last refreshed: 9 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05206422.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing